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HIV-2 is a nonpandemic form of the virus causing AIDS, and the majority of HIV-2-infected patients exhibit long-term nonpro-
gression. The HIV-1 and HIV-2 envelope glycoproteins, the sole targets of neutralizing antibodies, share 30 to 40% identity. As a
first step in understanding the reduced pathogenicity of HIV-2, we solved a 3.0-Å structure of an HIV-2 gp120 bound to the host
receptor CD4, which reveals structural similarity to HIV-1 gp120 despite divergence in amino acid sequence.
Human immunodeficiency virus type 1 (HIV-1) remains a threatto global public health. With no vaccine available, it dispropor-
tionately causesAIDS in thedevelopingworld.While the relatedvirus
HIV-2 is capable of generating full-blown AIDS, infection rates are
more localized and on the decline (1–4). In contrast to patients in-
fected with HIV-1, the majority of HIV-2-infected individuals re-
mainasymptomatic,with lowplasmaviral loads andnormalCD4T
cell counts (5–7). HIV-2 is a robust immunogen in natural infec-
tion, and patients readily make high-titer, broadly reactive, and
strongly neutralizing antibodies against primary strains, some-
thing rarely seen in HIV-1 infections (1–3). In addition, HIV-2
appears slower to evolve the neutralization-resistant variant
strains commonly found in HIV-1 infections (3, 8). The rate of
mother-to-child transmission is also much lower for HIV-2 (9),
and differential neutralizing activities found in patients dually in-
fected with HIV-1 and HIV-2 suggest the presence of distinct and
divergent immune responses against these related viruses (10).
The bulk of current investigative efforts are focused on HIV-1
due to its higher virulence and transmissibility. However, the im-
mune response in the context of HIV-2 infection may provide a
natural model of effective HIV control. While HIV-2 is not an
attenuated virus, infected patients seem to naturally exhibit char-
acteristics of a desired response to an effective therapy against
HIV. Therefore, a deeper understanding of the immune response
against HIV-2 could provide insight into how to elicit a similar
response against HIV-1. HIV-1 and HIV-2 share 30% overall se-
quence identity and 40% amino acid identity in their envelope
(Env) glycoprotein gp160 (1, 2, 11), which is the sole target of
neutralizing antibodies. Through structural studies of broadly
neutralizing antibodies against HIV-1, these antibodies have been
shown to target a variety of epitopes on the gp120 and gp41 sub-
units of HIV-1 gp160 (12) but do not generally cross-react be-
tween HIV-1 and HIV-2 (2, 13). Some HIV-1-induced CD4-in-
duced (CD4i) antibodies, which bind to the coreceptor binding
site exposed via a CD4-induced conformational change (14),
cross-react to neutralize several HIV-2 strains (13), suggesting
structural similarity in this portion of HIV-1 and HIV-2 Env.
However, some HIV-2 isolates can enter cells in a CD4-indepen-
dent manner (15), leading to the hypothesis that HIV-2 may have
a more open coreceptor binding domain (3).
Insights gained from theHIV-2model of elite viral controlmay
inform prophylactic and immunogen design for both forms of
HIV. However, to date, no three-dimensional (3D) structures of
HIV-2 Env have been reported. To investigate potential explana-
tions for its decreased pathogenicity and increased immunogenic-
ity compared with HIV-1 Env, we solved a 3.0-Å crystal structure
of an HIV-2 gp120 core from the ST strain (gp120ST) (16) in
complex with the first two domains of the host receptor CD4
(sCD4) and compared the structure to HIV-1 and SIV gp120 and
CD4/gp120 structures.
A gene corresponding to HIV-2 gp120ST (Los Alamos HIV
sequence database [http://www.hiv.lanl.gov]) wasmodified based
on the HIV-1 gp120 core used for crystallographic studies (11,
17–19). Core gp120ST contained deletions of the V1/V2 and V3
variable loops, 15 residues of the C terminus (11), and a mutation
(T89I) of a conserved potential N-linked glycosylation site
(PNGS) distal from predicted binding interfaces (Fig. 1). Core
gp120ST and sCD4 were expressed and purified as previously de-
scribed (20, 21) and then cocrystallized via sitting drop vapor
diffusion in a 1:1 mixture with 0.15 M DL-malic acid 7.0, 0.1 M
imidazole (pH 7.0), and 22% polyethylene glycol (PEG) MME
550. Crystals were cryopreserved in Fomblin Y (Sigma), and 3.0-Å
diffraction data (as determined by CC1/2 [22]) were collected at
the SSRL beamline 12-2 and processed using XDS (23) (Table 1).
Structure determination was performed by molecular replace-
ment in Phaser (24) using structures of HIV-1 gp120CAP210 (PDB
code 3LQA, chain G, 35% identical) and sCD4 D1D2 (2NXY,
chain B, 100% identical) as search models. (Molecular replace-
ment using the structure of an SIV gp120 [2BF1; 72% identical to
gp120ST] as a searchmodel yielded no solutions.)Manual rebuild-
ing guided by simulated annealing composite omit maps calcu-
lated using CNS (25) or Phenix.autosol (26) to minimize model
bias (27) was performed using COOT (28). Iterative rounds of
refinement were performed using Phenix.refine (26) and Refmac
(29) within the PDB_REDO server (30), including but not limited
to rigid body, group B factor, translation, libration, and screw-
rotation (TLS), real-space, and Rosetta-guided refinement algo-
rithms (31, 32) (Table 1).
TheHIV-2 core gp120ST structure (numbered according to the
SIVmac239 convention [33]) comprises 23-strands (1 to23),
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FIG 1 Structure and sequence ofHIV-2 gp120 core. (A)Diagramof the domain structure of the gp120 core, with locations of deleted loops indicated. Branch symbols
mark potential glycosylation sites. (B) Structure of the HIV-2 gp120 core, with polypeptide chains as ribbons, alpha helices as cylinders, and carbohydrates as stick
models. Disordered residues are shown as dashed lines. Domains are colored as in panel A. (Inset) Annealed omit electron density map in the vicinity of theN-glycan
attached to N295gp120-ST contoured at 1.5. (C) Alignment of the gp120 core sequences of HIV-2 and HIV-1 HxB2. Residues in blue are identical; those in green are
conservative substitutions (scoring 0.5 in the Gonnet PAM 250 matrix [49]). The mutation to remove a PNGS in HIV-2 is in red. Colors of secondary structure
elements correspond to colors in panels A and B. PNGS are marked as in panel A; sites with ordered sugars are indicated with black branch symbols, while sites with
disordered sugars are indicated with gray branch symbols.
February 2016 Volume 90 Number 4 jvi.asm.org 2113Journal of Virology
 o
n
 February 18, 2016 by CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y
http://jvi.asm.org/
D
ow
nloaded from
 
five -helices (1 to 5), five loop regions (A to E), truncated
variable loops V1 to V3, and disordered loops V4 and V5 (Fig. 1).
In comparisons with available HIV-1 and SIV gp120 structures,
we found that the gp120ST structure was more similar to gp120
structures from HIV-1 (PDB code 2NXY [34], 4P9H [20], 3LQA
[21], 2B4C [35], 1RZK [36], 3U7Y [37]) than to the structure of
SIVmac32H gp120 (2BF1 [19]), despite sharing only 35% se-
quence identity with HIV-1 gp120s compared with 72% identity
with SIVmac32H gp120 (11, 19) (Fig. 1C and 2D). Indeed, the
overall architecture of HIV-2 gp120ST was nearly identical to both
liganded and unliganded (PDB code 3TGT [17]) HIV-1 gp120
cores, with secondary structure elements comprising the inner
and outer domains adopting common conformations (Fig. 1).
When superimposed with HIV-1 gp120 core structures using se-
quence-based alignment in PyMOL (38), the core gp120ST struc-
ture yielded root mean square deviation (RMSD) values of 1.3 to
1.6 Å (Fig. 2). In contrast, the HIV-2 gp120ST structure aligned
poorly with the structure of unliganded SIVmac32H gp120 (19)
(RMSD 5.6 Å for 230 C atoms), and the-strands comprising
the bridging sheetwere shifted by 13 to 25Å, theV1/V2 stemswere
shifted by27 Å, the 1 helix was shifted by 15 Å, and the three-
stranded -sheet at the C terminus was offset by a 90° rotation
(Fig. 2A). We therefore used HIV-1 core gp120 structures for
comparisons with HIV-2 gp120ST.
Analysis of structural and sequence conservation between
gp120ST core and the seven most similar HIV-1 gp120 core struc-
tures in the PDB (4DVR, 3TGR, 1G9N, 3U7Y, 4JM2, 2NY0, and
1GC1) using ENDScript (39) showed high degrees of structural
conservation in most ordered regions. Notably, the coreceptor
binding footprint, which comprises the bridging sheet and sur-
rounding residues, showed nomajor differences between gp120ST
and HIV-1 gp120s. In the HIV-2 gp120ST structure, six conserved
disulfide bonds superimposed with their counterparts in HIV-1
gp120 core structures. Eight PNGSs showed ordered sugar resi-
dues (Fig. 2). Only two (N262HXB2 andN386HXB2) are also PNGSs
in HIV-1 gp120s.
It has been postulated that HIV-2 has a more open V3 loop
conformation thanHIV-1 due to the HIV-2 V3 loop having fewer
PNGSs (40). Core gp120ST has a truncated V3 stem with the same
number of residues as the truncated stem in HIV-1 gp12093TH057
(3U7Y) and 10 more residues than the V3 stem in HIV-1
gp120HXB2 (2NXY). The ST and HIV-1 93TH057 V3 stems of
equal length were superimposed with an RMSD of 0.46 Å. Thus,
characterizing differences in this region between HIV-1 and
HIV-2 would require future comparison of structures with intact
and orderedV3 loops. TheV4 andV5 loops, which are shorter and
less glycosylated in HIV-2 than in HIV-1, were completely disor-
dered in the gp120ST core structure. One of the most distinct
structural differences between HIV-2 and HIV-1 gp120 is the ex-
tended loop E of HIV-2 gp120, which emanates from the junction
between the2 helix and14 strand in the gp120ST core structure.
In alignments with loop E fromHIV-1 gp120 (Fig. 2C), ST loop E
was 3 to 5 residues longer and featured a turn not seen in HIV-1
gp120 structures.
Superposition of the gp120ST/sCD4 structure on three HIV-1
gp120/sCD4 structures revealed no notable global differences
in the orientation of sCD4 binding to gp120ST (RMSD values of
2 to 2.1 Å after aligning 350 to 380 C atoms from gp120 and
CD4) (Fig. 3). HIV-2 and HIV-1 gp120s share the same core
interactions with CD4, represented on CD4 by residues 40 to
60, including the C	 strand and residues F43CD4 and R59CD4,
and on gp120 by the CD4 binding loop, the F43CD4-binding
pocket, and the D386gp120-ST/368gp120-HXB2 (Fig. 4). However,
gp120 loop D, which makes close contacts with sCD4, differed
greatly between HIV-1 and HIV-2 (Los Alamos HIV sequence
database [http://www.hiv.lanl.gov]). Differences included overall
sequence, conformation, and glycosylation pattern. HIV-1 and
HIV-2 gp120 residue 280gp120-HXB2/295gp120-ST features a highly
conserved asparagine, which is the N-terminal residue of a
PNGS in nearly all HIV-2 strains but never in HIV-1 strains
(Los Alamos HIV sequence database [http://www.hiv.lanl
.gov]). Instead, HIV-1 strains usually have a PNGS at position
276gp120-HXB2. The different loop D sequences are reflected in
several differences in the gp120-sCD4 interaction. HIV-1 loop D
and the pre-V523 strand interactwithCD4 residues 29 to 35, but
these interactions are absent in HIV-2. Conversely, HIV-2 gp120
has CD4 interactions that do not occur in HIV-1: loop D residue
R293gp120-ST interacts with E87CD4 and D88CD4. Also, the BC loop
of CD4 (residues 19 to 25), which in other CD4 structures (11, 20,
36) (including structures of CD4 alone [41–43]) is packed against
the CD4 DE loop, is displaced6 Å toward HIV-2 gp120, inter-
acting with E84gp120-ST and N79gp120-ST near the beginning of the
1 helix.
Given the difference in pathogenicity between HIV-1 and
HIV-2 (3) and the highly distinct unliganded SIV gp120 struc-
ture (19), we expected larger differences between the gp120
structures of the two human viruses. Because the unexpected
similarities between HIV-1 and HIV-2 gp120s do not explain
the difference in virulence between HIV-1 and HIV-2 (1–4),
the decreased virulence of HIV-2 may relate to structural dif-
ference outside the gp120 core or to other differences between
TABLE 1 Data collection and refinement statistics for gp120ST/sCD4
Statistic Value for gp120ST/sCD4
a
Data collection
Resolution (Å) 35–3.0 (3.1–3.0)
Space group C2221
Unit cell a 94.3 Å; b 100 Å; c 199 Å
Total reflections 85,946 (8,705)
Unique reflections 19,116 (1,901)
Completeness (%) 99.2 (99.7)
Mean I/(I) 12.8 (2.57)
Rmerge 0.081 (0.82)
CC½ 1.0 (0.84)
CC* 1.0 (0.96)
Refinement
Rwork (%) 23.6
Rfree (%) 28.3
No. of atoms 3,859
No. of protein residues 445
No. of glycan residues 11
RMSDb bonds (Å) 0.42
RMSDb angles (°) 0.70
Ramachandran favoredc (%) 93
Ramachandran allowedc (%) 6.6
Ramachandran outliersc (%) 0.4
Average B factor (Å2) 103.0
a Statistics for the highest-resolution shell are shown in parentheses.
b RMSD, root mean square deviation.
c Defined by MolProbity.
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the two classes of virus. If decreased virulence is related at least
in part to Env structure, differential immune activation could
result from differences in the variable loops, which are trun-
cated or disordered in gp120 core structures, and/or fewer N-
linked glycans resulting in decreased glycan shielding of the
HIV-2 V3 and V4 loops (40). As demonstrated in X-ray and EM
structures of trimeric HIV-1 Env (44–48), quaternary interac-
tions outside the context of monomeric gp120 likely also play
key roles in the behavior of HIV-2.
Due to the robust neutralizing antibody response to HIV-2
FIG 2 Superposition of HIV-2, HIV-1, and SIV gp120 structures. (A) (Left) Sequence-based alignment of HIV-2ST gp120 core (green) with liganded and
unliganded HIV-1 gp120 cores (gray) shows structural similarity. (Right) The SIVmac32H gp120 core from same viewpoint shows several secondary structural
elements with different conformations. (B andC) Alignment of loops D and E fromHIV-1 (various colors) andHIV-2 (mint green). (D) Alignment of the gp120
core sequences ofHIV-2 and SIV. Residues in blue are identical; those in green are conservative substitutions (scoring0.5 in theGonnet PAM250matrix [49]).
Colors of secondary structure elements correspond to colors in Fig. 1A. PNGSs aremarked as in Fig. 1C; sites with ordered sugars are indicated with black branch
symbols, while sites with disordered sugars are indicated with gray branch symbols.
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(1–3), it is likely that differences in pathogenicity are due, at least
in part, to the role of the Env glycoprotein. This is encouraging for
the future growth of HIV-2 knowledge, as the HIV field has long
been focused and is well equipped for conducting comprehensive
structural studies of the interactions between Env and its binding
partners. Further X-ray crystallographic or EM studies involving
neutralizing antibodies against HIV-2 Env should provide greater
insight into this intriguing model of viral control.
FIG 3 Conservation of the CD4 binding site. (A) Superposition ofHIV-2ST gp120 core in complex with sCD4 (green) with analogousHIV-1 cocrystal structures
(gray). (B and C) Polar contacts within the gp120ST/CD4 (left) and gp120HIV-1/CD4 (right) binding interface. (D) Superposition of CD4-binding loops from
HIV-2 and HIV-1 gp120 core/CD4 complex structures (colors are as in Fig. 2B).
FIG 4 Buried per-residue accessible surface area of CD4 upon binding to HIV-2 (blue) or HIV-1 (pink) gp120. Althoughmuch of the buried interface is shared,
there are residues that are contacted by only HIV-1 or HIV-2 gp120. The CCP4 programAREAIMOL (mode DIFFMODECOMPARE) was used to calculate the
per-residue difference in accessible surface area (1.4-Å probe radius) for CD4 upon complex formationwith Env. HIV-1 coordinates were fromPDB entry 1RZJ.
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Protein structure accession number. Coordinates and X-ray
crystallographic data for ST gp120/sCD4 have been deposited in
the Protein Data Bank with accession number 5CAY.
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